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Edited by Horst FeldmannAbstract An increasing number of ion channels are being found
to be causally involved in diseases, giving rise to the new ﬁeld of
‘‘channelopathies’’. Cancer is no exception, and several ion chan-
nels have been linked to tumour progression. Among them is the
potassium channel EAG (Ether-a-go-go). Over 75% of tumours
have been tested positive using a monoclonal antibody speciﬁc for
EAG, while inhibition of this channel decreased the proliferation
of EAG expressing cells. The inhibition of EAG is accomplished
using RNA interference, functional anti-EAG1 antibodies, or
(unspeciﬁc) EAG channel blockers. Fluorescently labelled re-
combinant Fab fragments recognizing EAG allow the distribu-
tion of EAG to be visualized in an in vivo mouse tumour model.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Near-infrared imaging1. Historical overview
A growing number of ion channels are being implicated in
tumor progression, with sodium and potassium channels
among them. With respect to potassium channels, it has been
postulated that they are important for proliferation since they
inﬂuence cell volume [1]. However, this would be a general
mechanism that applies to all types of potassium channels,
and this is not the case [2]. To date, over 70 types of potassium
channels are known [3], but only a few have been directly
implicated in cell proliferation and tumour growth. The best
studied cases include Kv1.3 (KCNA3) [4–8], IKCa1 (KCa3.1,
KCNN4) [9], TASK-3 (K2P9.1, KCNK9) [10], HERG
(Kv11.1, KCNH2) [11–15] and EAG1 (KV10.1, KCNH1)
[16,18]. Taking EAG as an example, what is the evidence for
its involvement in cell proliferation and tumour progression?2. EAG is involved in cell cycle and proliferation
Initially, it was observed that the activation kinetics of EAG
markedly depend on the holding potential, becoming more ra-
pid at depolarized potentials [19], and that the Drosophila var-*Corresponding author. Fax: +49 551 3899 644.
E-mail address: wstuehm@gwdg.de (W. Stu¨hmer).
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2006.03.062iant is permeable to potassium and calcium, as well as being
modulated by cAMP [20]. In addition, extracellular magne-
sium concentrations are able to modulate the kinetics [21].
The ﬁrst indications that EAG is involved in the cell cycle
came from the observation that mitosis-promoting factor af-
fects the amount of current through this channel [22] and that
the particular cell-cycle stage modulates its selectivity to cae-
sium and block by intracellular sodium [23]. Furthermore,
the microtubule depolymerization that occurs during mitosis
produces similar eﬀects [24], further strengthening the evidence
that EAG is modulated during cell cycle.
Similarly to most potassium channels, EAG subunits form a
functional channel when assembled into tetramers. Given that
there is another human isoform of EAG, EAG2, heteromulti-
meric channels comprised of EAG1 and EAG2 can be formed.
The speciﬁcity of this interaction is determined by the C-termi-
nally located tetramerizing coiled–coiled (TCC) domain which
also determines the possible tetramer composition, as it for
example precludes the formation of functional channels com-
posed of EAG and HERG subunits [25]. During these studies,
it became evident through electrophysiological measurements
that few functional EAG channels exist despite the fact that sig-
niﬁcant intracellular levels of EAG protein could be detected.
This discrepancy is probably caused by the retention of EAG
in the ER (which would be consistent with the fact that the
EAG sequence contains an ER-retention signal LRKR [26]),
and modulation of its traﬃcking by glycosylation [27].3. Inhibition of currents through EAG
Outside the CNS, EAG is a speciﬁc marker for tumor tissue
[16–18] and its inhibition by astemizole or the tricyclic antide-
pressant imipramine reduces the proliferation of tumor cells
[28,29]. Obviously, an EAG inhibitor would be a helpful tool
for the development of diagnostic and therapeutic agents and
therefore the blocking mechanism of EAG1 channels by
astemizole and imipramine was investigated in detail [30].
Unfortunately, these substances are unspeciﬁc and also aﬀect
the human EAG-related gene product, HERG.
Another strategy is the development of speciﬁc antibodies that
recognize the extracellularly accessible tumor markers. The eﬃ-
ciency and convenience of the use of antibodies against tumor-
speciﬁc markers, such as HER-2/neu, are sometimes combined
with other chemotherapeutics to increase response rates or re-
duce the eﬀective dose [31]. Recent advances in near-infrared
ﬂuorescent (NIF) imaging [32], in combination with speciﬁcblished by Elsevier B.V. All rights reserved.
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mals. For this approach, the antibodies need to be labeled with
infrared emitting dyes such as AlexaFluor 680 or Cy5.5.
We tested this approach by labeling a monoclonal antibody
speciﬁc for EAG1 with a secondary antibody labeled with
AlexaFluor 680 [33]. The resulting complex was injected into
immuno-suppressed mice grafted with MBA-MB-413S human
mammary carcinoma cells (which are positive for EAG1
expression) as a tumor model. Twenty-four hours after injec-
tion of 100 lg of the anti-EAG1–Alexaﬂuor complex, the pri-
mary tumor as well as the corresponding sentinel node, was
clearly visible (see Fig. 1). This indicates the association of this
NIF complex with the extracellular EAG1 epitope [33].4. Fluorescently labeled single chain anti-EAG antibody
A disadvantage of this approach is the large size of the ﬂuo-
rescent complex that consists of two complete antibodies and
the conjugated ﬂuorescent dye. Direct labeling of the antibody
with the ﬂuorescent dyes caused a signiﬁcant reduction in aﬃn-
ity, possibly due to their conjugation to several lysine residues
present in the antibody’s complementarity determining regions
(CDR’s). We have addressed this issue by generating a recom-
binant single-chain anti-EAG1 antibody comprising only the
Fab’ domain, which did not signiﬁcantly diﬀer in either aﬃnity
or speciﬁcity to the whole antibody, and to which a poly-lysine
chain was linked, thereby increasing the labeling eﬃciency. In
this way, a much smaller anti-EAG1–Cy5.5 complex was gen-Fig. 1. False-color image of NIR intensities from Cy5.5 conjugated to
anti-EAG Fab fragment 24 h after i.v. injection of the conjugate. The
mouse had been grafted with MBA-MB-435 cells and a palpable
tumour had just developed. A shift towards the red indicates higher
intensities. The lifetime of the ﬂuorescence observed corresponds to
Cy5.5.erated, which can more easily penetrate dense tumour tissue.
In addition, it is also now possible to produce an engineered
protein consisting of the single-chain antibody and a modiﬁed
ﬂuorescent protein with red-shifted spectrum.5. In vivo imaging of EAG
Fig. 1 shows an image of a mouse 24 h after i.v. injection of a
poly-lysine containing recombinant anti-EAG1-Fab’ fragment I
conjugated to Cy5.5. The immunodeﬁcientmouse had previously
been grafted with MBA-MB-435S cells. The false colors corre-
spond toNIR intensities obtained using an eXploreOptix System
(General Electric Healthcare, London, Canada). The mouse was
anaesthetized by inhalation of isoﬂuorane, a procedure that can
be applied repeatedly without harming the living animal.
In summary, EAG is a novel and highly signiﬁcant tumour
marker that has diagnostic and therapeutic potential. Being a
potassium channel, it is extracellularly accessible and can be
molecularly labelled in vivo using NIR imaging.
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